Indian Journal of Research in Homoeopathy
Keywords
Homoeopathy; Pathogenetic response; Homoeopathic pathogenetic trial: Drug Proving, Mimosa humilis
Article Type
Original Article
Abstract
Objective: To elicit the pathogenetic response of the drug Mimosa humilis in homoeopathic potencies on healthy human beings. Methodology: Drug Mimosa humilis was proved through double-blind placebo-controlled method. The study was conducted at 2 centers. The drug was proved in two potencies (6C and 30C) on 16 apparently healthy volunteers who were selected after pre-trial medical examination by the specialists and after doing routine pathological investigations. The volunteers consumed 56 doses (04 doses per day for 14 days) of each potency in three phases (including 1" phase in placebo) for a varying period. The symptoms generated during the trial period were noted by the volunteers and elaborated and cross examined by the Proving Masters. The data obtained from both the centers was compiled at proving-cum-data processing cell at CCRH headquarters after de-coding. Observations: Out of the 10 provers who were on actual drug trial, 05 manifested symptoms. Drug was able to produce symptoms in each potency more or less on every part of the body. Some of the symptoms have been reproved which are mentioned in different literatures after fragmentary proving. Conclusion: Pathogenetic responses, elicited (new and reproved) during the proving trial will add to the literature available on the drug and benefit the research scholars and clinicians. This also needs verification through clinical trials.
Digital Object Identifier
10.53945/2320-7094.2261
Publisher
Central Council for Research in Homoeopathy
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 4.0 International License.
How to cite this article
Nayak C, Singh V, Siddiqui V, et al. Mimosa humilis: A multicentric double blind Homoeopathic Pathogenetic Trial. Indian J Res Homoeopathy 2009;3:16-20. doi: 10.53945/2320-7094.2261
